

**Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with
Type 2 Diabetes and Their Further Characterisation – Cross-sectional study from
Slovakia**

Mariana Rončáková^{a,b}, Arash Davani^a, Veronika Mikušová^{a,c}, Ivana Ságová^{a,b}, Peter Novodvorský^{d,e*}, Emil Martinka^{a*}

^aNational Endocrinology and Diabetology Institute (NEDÚ), Ľubochňa, Slovakia, ^bJessenius Faculty of Medicine in Martin, Comenius University Bratislava, Slovakia, ^cFirst Department of Medicine, University Hospital Martin, Martin, Slovakia, ^dDiabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, ^eDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom

*Peter Novodvorský and Emil Martinka are joint senior authors

ORCID numbers (where available)

Peter Novodvorský 0000-0002-3292-7586

Emil Martinka 0000-0002-3942-8587

Corresponding author: Emil Martinka

National Endocrinology and Diabetology Institute (NEDÚ), Ľubochňa 144, 03491, Slovakia

E-mail: martinka@nedu.sk

Table 1. Additional baseline characteristics of the study population

Total daily dose of insulin (IU)	62 (0 - 150)	Coronary revascularisation	93 (13.4%)
Time to insulin initiation from diagnosis (years) (n=407)	8.0 (0 - 32.0)	Adrenal pathology (any), n (%)	10 (1.4%)
Non-diabetic medication, n (%)		Autoimmune thyroiditis, n (%)	100 (14.5%)
statins	415 (60%)	TPO AA positivity (n=350)	46 (13.1%)
fibrates	94 (13.6%)	Thyroglobulin AA positivity (n=351)	41 (11.7%)
ACEi	300 (43.4%)	Coeliac disease, n (%)	6 (0.9%)
ARB	248 (35.8%)	Hyperuricaemia, n (%)	113 (16.3%)
beta blockers	375 (54.2%)	*Number of all hypoglycaemias in 7 days	0.66 ± 1.49 (0 - 11)
calcium channel blockers	287 (41.5%)	part. with no hypoglycaemia, n (%)	503 (73.8%)
diuretics	381 (55.1%)	part. with ≥1 hypoglycaemia, n (%)	179 (26.2%)
alpha blockers	58 (8.4%)	Number of nocturnal hypoglycaemias in 7 days	0.03 ± 0.21 (0 - 2)
imidazoline receptor agonists	140 (20.2%)	part. with no nocturnal hypoglycaemia, n (%)	666 (97.7%)
acetylsalicylic acid	206 (29.8%)	part. with ≥1 nocturnal hypoglycaemia, n (%)	16 (2.3%)
clopidogrel	75 (10.8%)	Number of SH in 7 days	0.03 ± 0.29 (0 - 6)
oral anticoagulants	48 (6.9%)	part. with no SH, n (%)	674 (98.8%)
Arterial hypertension, n (%)	611 (88.3%)	part. with ≥1 SH	8 (1.2%)
Ischaemic stroke, n (%)	47 (6.8%)	Number of nocturnal SH in 7 days	0.02 ± 0.18 (0 - 2)
Ischaemic heart disease, n (%)	298 (43.1%)	part. with no nocturnal SH, n (%)	675 (98.9%)
Acute coronary syndrome, n (%)	90 (13.0%)	part. with ≥1 nocturnal SH, n (%)	7 (1.0%)
Heart failure, n (%)	45 (6.5%)	Coronary revascularisation	93 (13.4%)

Data are reported as n (%), median (range) or mean ± SD (range) depending on the normality of their distribution

* for all hypoglycaemia characteristics the total number of participants analysed is 682

Abbreviations: AA, autoantibodies; ACEi, Angiotensin-converting enzyme inhibitors; ARB, Angiotensin II receptor blockers; IU, international units; part., participants; SH, severe hypoglycaemia; TPO, thyroid peroxidase

Supplementary Table 2. Correlations of anti-GAD₆₅ titre with other characteristics in anti-GAD₆₅ positive individuals

anti-GAD₆₅ titre vs.	Spearman`s rho	95% CI	p value*
Time to insulin initiation from diagnosis	-0.508	-0.342, -0.644	<0.001
Weight	-0.380	-0.226, -0.515	<0.001
Waist circumference	-0.367	-0.209, -0.507	<0.001
HDL cholesterol	0.347	0.487, 0.189	<0.001
Fasting c-peptide levels	-0.320	-0.160, -0.463	<0.001
Fasting triglycerides	-0.309	-0.148, -0.454	<0.001
Number of all hypoglycaemias in 7 days	0.307	0.452, 0.146	<0.001
BMI	-0.267	-0.103, -0.417	0.002
Total daily dose of insulin	-0.256	-0.077, -0.419	0.006
TPO autoantibody titre	0.256	0.457, 0.029	0.028
Duration of diabetes	-0.251	-0.086, -0.403	0.003
Age at diagnosis of diabetes	0.214	0.370, 0.047	0.012
Total cholesterol	0.177	0.335, 0.009	0.039
Number of nocturnal hypoglycaemias in 7 days	0.066	0.232, -0.103	0.445
HbA _{1C}	-0.109	0.061, -0.273	0.208
LDL cholesterol	0.048	0.215, -0.122	0.581
TSH	0.038	0.243, -0.171	0.725

*n=136 for all comparisons

Abbreviations: BMI, Body Mass Index; HbA_{1C}, glycated haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; TPO, thyroid peroxidase; TSH, thyroid stimulating hormone.

Supplementary Table 3. Correlations of fasting c-peptide levels with other characteristics in anti-GAD₆₅ positive individuals

Fasting c-peptide levels vs.	Spearman`s rho	95% CI	p value*
Time to insulin initiation from diagnosis	0.420	0.573, 0.239	<0.001
Number of all hypoglycaemias in 7 days	-0.412	-0.262, -0.543	<0.001
Fasting triglycerides	0.379	0.515, 0.224	<0.001
Weight	0.333	0.474, 0.174	<0.001
HDL cholesterol	-0.328	-0.168, -0.471	<0.001
Waist circumference	0.311	0.458, 0.147	<0.001
BMI	0.280	0.429, 0.116	0.001
TPO autoantibody titre	-0.197	0.033, -0.407	0.093
Age at diagnosis of diabetes	0.172	0.332, 0.003	0.046
Number of nocturnal hypoglycaemias in 7 days	0.065	0.230, -0.105	0.455
LDL cholesterol	0.053	0.220, -0.117	0.539
Total daily dose of insulin	0.036	0.217, -0.149	0.706
Total cholesterol	0.035	0.202, -0.134	0.684
Duration of diabetes	-0.139	0.030, -0.301	0.107
HbA _{1C}	-0.111	0.059, -0.275	0.199
TSH	-0.098	0.112, -0.299	0.359

*n=136 for all comparisons

Abbreviations: BMI, Body Mass Index; HbA_{1C}, glycated haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; TPO, thyroid peroxidase; TSH, thyroid stimulating hormone